Enovis (NYSE:ENOV) Issues FY 2025 Earnings Guidance

Enovis (NYSE:ENOV) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided EPS guidance of 3.100-3.250 for the period, compared to the consensus EPS estimate of 3.160. The company issued revenue guidance of $2.2 billion-$2.2 billion, compared to the consensus revenue estimate of $2.2 billion.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC reiterated a “buy” rating and set a $65.00 target price on shares of Enovis in a research report on Thursday, November 7th.

Enovis Price Performance

ENOV traded down $1.53 during trading on Wednesday, hitting $40.58. The company’s stock had a trading volume of 1,063,454 shares, compared to its average volume of 959,522. The company has a quick ratio of 1.12, a current ratio of 2.27 and a debt-to-equity ratio of 0.40. The stock has a market capitalization of $2.31 billion, a price-to-earnings ratio of -18.53 and a beta of 1.94. The firm’s 50 day moving average price is $44.96 and its two-hundred day moving average price is $44.37. Enovis has a 12 month low of $38.27 and a 12 month high of $63.96.

Enovis (NYSE:ENOV) last announced its earnings results on Wednesday, February 26th. The company reported $0.98 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.92 by $0.06. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. Sell-side analysts forecast that Enovis will post 2.79 earnings per share for the current fiscal year.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.